295 related articles for article (PubMed ID: 15685669)
1. Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget.
Zaric GS; O'brien BJ
Health Econ; 2005 Aug; 14(8):793-803. PubMed ID: 15685669
[TBL] [Abstract][Full Text] [Related]
2. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
3. Role of budget impact in drug reimbursement decisions.
Cohen JP; Stolk E; Niezen M
J Health Polit Policy Law; 2008 Apr; 33(2):225-47. PubMed ID: 18325899
[TBL] [Abstract][Full Text] [Related]
4. A comparative analysis of the impact of a positive list system on new chemical entity drugs and incrementally modified drugs in South Korea.
Ha D; Choi Y; Kim DU; Chung KH; Lee EK
Clin Ther; 2011 Jul; 33(7):926-32. PubMed ID: 21715008
[TBL] [Abstract][Full Text] [Related]
5. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
Kim ES; Kim JA; Lee EK
Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
[TBL] [Abstract][Full Text] [Related]
6. [Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals].
Hammerman A; Greenberg D
Harefuah; 2012 Jun; 151(6):364-7, 376. PubMed ID: 22991869
[TBL] [Abstract][Full Text] [Related]
7. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
Hoomans T; van der Roer N; Severens JL; Delwel GO
Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
[TBL] [Abstract][Full Text] [Related]
8. Focusing pharmacoeconomic activities: reimbursement or the drug life cycle?
Langley PC
Curr Med Res Opin; 2004; 20(2):181-8. PubMed ID: 15006012
[TBL] [Abstract][Full Text] [Related]
9. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
Führlinger S
Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
[TBL] [Abstract][Full Text] [Related]
10. [Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies].
Castillo-Laborde C; Silva-Illanes N
Rev Med Chil; 2014 Jan; 142 Suppl 1():S33-8. PubMed ID: 24861178
[TBL] [Abstract][Full Text] [Related]
11. The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare.
Critchley GJ; Zaric GS
Health Econ; 2019 Aug; 28(8):1035-1051. PubMed ID: 31310424
[TBL] [Abstract][Full Text] [Related]
12. Applying Programme Budgeting Marginal Analysis in the health sector: 12 years of experience.
Grocott R
Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):181-7. PubMed ID: 19402806
[TBL] [Abstract][Full Text] [Related]
13. An application of a proposed framework for formulary listing in low-income countries: the case of Côte d'Ivoire.
Diaby V; Lachaine J
Appl Health Econ Health Policy; 2011 Nov; 9(6):389-402. PubMed ID: 22017499
[TBL] [Abstract][Full Text] [Related]
14. Need for an improved submission process for listing drugs for reimbursement in Canadian provinces.
West R; Borden EK; Collet JP; Rawson NS; Tonks RS
Can J Clin Pharmacol; 2003; 10(4):207-10. PubMed ID: 14712327
[TBL] [Abstract][Full Text] [Related]
15. Drug pricing and value in oncology.
Danzon PM; Taylor E
Oncologist; 2010; 15 Suppl 1():24-31. PubMed ID: 20237214
[TBL] [Abstract][Full Text] [Related]
16. Prediction of Medicare drug formulary drugs for treatment of overactive bladder.
Grocela JA; Kanji A; Ternullo J
J Urol; 2006 Jul; 176(1):252-5; discussion 255-6. PubMed ID: 16753413
[TBL] [Abstract][Full Text] [Related]
17. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2008 Jan; ():1-23. PubMed ID: 18345558
[No Abstract] [Full Text] [Related]
19. Estimating the budget impact of new technologies added to the National List of Health Services in Israel: stakeholders' incentives for adopting a financial risk-sharing mechanism.
Hammerman A; Greenberg D
Health Policy; 2009 Jan; 89(1):78-83. PubMed ID: 18579253
[TBL] [Abstract][Full Text] [Related]
20. Pricing and reimbursement of pharmaceuticals in Italy.
Folino-Gallo P; Montilla S; Bruzzone M; Martini N
Eur J Health Econ; 2008 Aug; 9(3):305-10. PubMed ID: 18566845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
